1295
In August 1997, the patient relapsed with FAB-M2 AML. Karyotypic analysis revealed t(8;21) and RT-PCR was positive only for AML 1/ETO transcripts; the immunopheontype of the blasts was: CD34: 92%, CD33: 2%, CD13: 56%, CD15: 3%, CD56: 36%, CD19: 60%, HLA-DR: 98%, CD34/CD56: 34%. The patient attained complete remission with idarubicin and Ara-C and then, in November 1997, she underwent allogeneic bone marrow transplantation from an HLAcompatible sibling. However, she relapsed again in June 1998 with FAB-M2 AML and died 2 months later.
Conventional cytogenetics detect t(15;17) in APL with a sensitivity of 70-80%; even when cytogenetic analysis fails, as seems to have happened in our patient at diagnosis, PML/RAR␣ fusion is always identified by fluorescence in situ hybridization (FISH) or molecular biology techniques and denotes patients who are likely to respond to ATRA treatment. Based on the available cytogenetic data, it is not possible to discriminate whether the two genetic aberrations identified in our patient by RT-PCR were present in the same or in distinct clones. However, if the first alternative was true, one would expect RT-PCR to detect PML/RAR␣ chimeric transcripts along with AML1/ETO transcripts. Whatever the case, in agreement with Bonomi et al, 5 it is reasonable to speculate that combined ATRA/chemotherapy eliminated the APL clone but did not prevent progression or recurrence of the M2 clone that already existed at disease presentation. In conclusion, we feel that the similarities between the case reported by Bonomi et al and our patient are striking. Furthermore, the data presented above justify calling our case a M3:M2 chimeric AML.
N Stavroyianni
First 1 have elegantly demonstrated that an isoform of the proto-oncogene PML, PML-F12, is involved in antigen processing by controlling the expression of genes devoted to MHC class I antigen presentation, LMP-2, LMP-7, TAP-1 and TAP-2. Indeed, they confirm that the absence of MHC class I antigens on a plasmocytoma cell line (REB27) is due to a mutated form of this isoform (mutation G at position 962). They further suggest that the absence of MHC class I antigens on the cell surface of the AML3 leukemic cell line (NB4) could result from the presence of the PML-RAR␣ onco- Unfortunately, this information cannot be further extended to AML3 leukemias as we present here evidence that fresh AML3 leukemic cells, bearing the t(15;17) and molecularly defined as bearing either the short PML-RAR␣ (bcr3) or long PML-RAR␣ (bcr1) fusion genes are HLA A-B-C positive (79.3% ± 17.5% and 83.6% ± 12.9%, respectively). Likewise, the original NB4 cell line and the one currently used in our laboratory express HLA A-B-C (80%, range 70%-85%) as reported in the initial publication. 2 Moreover, upon differentiation with all-trans retinoic acid, no modulation of the percentage of positive cells or the intensity of labelling (correlating with the number of sites expressed at the cell surface) was observed ( Figure 1 and data not shown).
The great number of PML isoforms identified 3 suggest maybe multiple tissue-specific functions for PML. PML-RAR␣ transcripts expressed in APL patients are relatively homogenous (PML breakpoint observed in intron 6, bcr1 or in intron 3, bcr3 subtype). A patient with a t(15;17) translocation resulting in fusion gene which mimicks the mutated PML-F12 isoforms fused to the RAR␣ gene would be extremely rare. However it is not impossible that such a mutation may be either obtained or predominant in vitro and present in the NB4 clone on which Zheng et al have based their results. Indeed, though the PML-F12 isoform is apparently expressed in normal tissues, the mutant form was isolated from a tumor cell line.
Figure 1
HLA A-B-C antigen expression during in vitro differentiation with ATRA 10 −7 m. APL cells isolated from patients harboring either bcr1 or bcr3 PMLRAR␣ subtype were cultured 6 days in the absence (grey bars) or in the presence of ATRA 10 −7 m (white bars). Each bar represents the mean ± s.d. of HLA A-B-C expression for all patients (n = 10).
First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany

TO THE EDITOR
We report the first non-imported HTLV-1 positive adult T cell leukemia/lymphoma in Germany. A 41-year-old German mother of a healthy 12-year-old girl was admitted for generalized lymphadenopathy, splenomegaly, a macular exanthema and fever, all having developed within the past 2 weeks. The patient was confused and somnolent. No other abnormalities were observed at physical examination. Radiological assessment revealed a bilateral mediastinal lymph node enlargement. A magnetic resonance imaging (MRI) of the skull disclosed no abnormalities. Laboratory analyses displayed a normal hemoglobin and thrombocyte count, leukocytes were 45 G/l with 36% atypical flower-like lymphoid cells, creatinine was 2.04 (normal range: 0.3-1.0) mg/dl and calcium was 4.43 (2.10-2.60) mmol/l, lactate dehydrogenase was also elevated with 800 (230-400) U/l. Immunophenotyping of peripheral blood mononuclear cells identified the atypical cells as CD3
− mature T cells. Histologic examination of a lymph node biopsy showed an architecture destroyed by a CD3 + and BCL-2
− and CD15 − peripheral T cell lymphoma with a growth rate of 40%. The bone marrow biopsy disclosed an extended infiltration by the malignant T cell population. Pleocytosis and blasts were also seen in the cerebrospinal fluid (CSF). Antibodies against HTLV-1/2 were found in CSF and serum. A Western blot identified the characteristic anti-HTLV-1 band pattern both in patient's serum and CSF. Type-specific PCR analysis targeted to fragments of pol identified HTLV-1 as the integrated virion. High serum levels of soluble interleukin-2 receptor (s-IL-2R) as well as soluble tumor necrosis factor receptor type II (s-TNF R II) were recorded (Immulite, DPC Biermann, Germany). The patient had no history of i.v. drug abuse, blood transfusion or contact to residents of HTLV-1 endemic areas. The serology for HIV-1/2 and HBV was negative, while IgG antibodies were detected against VZV, CMV and EBV. Cytogenetic studies of peripheral blood lymphocytes (PBL) revealed consistent structural aberrations. The aberrant karyotype was: 46,X?ins(X;9)(q27;q21q33), +der(7;18)(q10;q10),-14, der(14) t(14;14)(q11;q32.1). After PstI/XhoI digestion of genomic DNA purified from pre-therapy PBL, Southern blot analysis indicated a 9 kb DNA fragment ( Figure 1, lane 3) suggesting clonal integration of the HTLV-1 provirus. After diagnosis of an acute ATLL and correction of the electrolyte imbalance, a chemotherapy according to the CHOP protocol (cyclophosphamide 1200 mg day 1, doxorubicin 80 mg day 1, vincristine 2 mg day 1, prednisone 180 mg days 1-5) in 3-week intervals as well as intrathecal (i.th.) instillations of methotrexate (MTX) 15 mg, cytarabin Ara-C 40 mg and dexamethasone 4 mg on days 1 and 8 of CHOP was initiated. A rapid improvement of the clinical status and laboratory parameters was achieved (Figure 2 ). Complete remission was documented after three courses of CHOP and six i.th. instillations. After a total of four courses of CHOP and eight i.th instillations a maintenance therapy with zidovudine 4 × 250 mg and interferon-␣ (IFN-␣) 5 × 10 6 U s.c. 1 was begun. Two months later the patient was readmitted with seizures and a peripheral dysesthesia. A MRI disclosed lesions in the right orbita and optical nerve, CSF microscopy showed leukemic meningiosis, thus a radiotherapy of the right orbita, skull and neuroaxis with a total of 28 Gy was initiated. The treatment was complicated by a bilateral invasive pulmonary aspergillosis treated with amphotericin B. No further antileukemic therapy was implemented and the patient was treated symptomatically. The patient died of fungal septicemia 10 months after initial diagnosis.
The rapid disease progression and short survival are typical of the acute form of ATLL. Furthermore, the translocation t(14;14) (q11;q32.1) is a typical chromosome aberration of ATLL resulting in an upregulation of the TCL-1 gene by juxtaposition next to the PCR-␣/␦-locus; while trisomy 7q due to a whole arm translocation between 7q and 18q is associated with the acute form of ATLL. 3 Although a complete remission was achieved with systemic and intrathecal chemotherapy, a maintenance therapy with zidovudine/ IFN-␣ did not prevent an early CNS relapse. Therefore, similar to the treatment of acute lymphoblastic leukemias, prolonged cytostatic treatment and early CNS radiotherapy might be beneficial in the treatment of ATLL with initial CNS involvement.
The disease activity and high tumor load was reflected by the serum levels of LDH, s-IL-2R 4 and s-TNF R (Figure 2 ). However, increasing
